APA (7th ed.) Citation

Chang, C., Chen, C., Chang, S., Chen, C., Lai, Y., Chang, C., & Wei, Y. (2023). Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment. Frontiers in Oncology, 13, . https://doi.org/10.3389/fonc.2023.1104098

Chicago Style (17th ed.) Citation

Chang, Cheng-Yu, Chung-Yu Chen, Shih-Chieh Chang, Ching-Yi Chen, Yi-Chun Lai, Chun-Fu Chang, and Yu-Feng Wei. "Factors Associated with Outcomes of Second-line Treatment for EGFR-mutant Non-small-cell Lung Cancer Patients After Progression on First- or Second-generation EGFR-tyrosine Kinase Inhibitor Treatment." Frontiers in Oncology 13 (2023). https://doi.org/10.3389/fonc.2023.1104098.

MLA (9th ed.) Citation

Chang, Cheng-Yu, et al. "Factors Associated with Outcomes of Second-line Treatment for EGFR-mutant Non-small-cell Lung Cancer Patients After Progression on First- or Second-generation EGFR-tyrosine Kinase Inhibitor Treatment." Frontiers in Oncology, vol. 13, 2023, https://doi.org/10.3389/fonc.2023.1104098.